DK3972604T3 - Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria - Google Patents

Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria

Info

Publication number
DK3972604T3
DK3972604T3 DK20729204.6T DK20729204T DK3972604T3 DK 3972604 T3 DK3972604 T3 DK 3972604T3 DK 20729204 T DK20729204 T DK 20729204T DK 3972604 T3 DK3972604 T3 DK 3972604T3
Authority
DK
Denmark
Prior art keywords
treatment
tyrosine kinase
kinase inhibitors
chronic spontaneous
spontaneous urticaria
Prior art date
Application number
DK20729204.6T
Other languages
Danish (da)
English (en)
Inventor
Souvik Bhattacharya
Bruno Bieth
Maciej Cabanski
Bruno Cenni
Buck Stefan De
Martin Kaul
Arvind Kinhikar
Andrijana Radivojevic
Thomas Severin
Julian Storim
Garami Alessandra Vitaliti
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3972604T3 publication Critical patent/DK3972604T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK20729204.6T 2019-05-23 2020-05-20 Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria DK3972604T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962851996P 2019-05-23 2019-05-23
PCT/IB2020/054755 WO2020234782A1 (en) 2019-05-23 2020-05-20 Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
DK3972604T3 true DK3972604T3 (da) 2025-09-15

Family

ID=70918751

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20729204.6T DK3972604T3 (da) 2019-05-23 2020-05-20 Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria

Country Status (22)

Country Link
US (2) US12419889B2 (https=)
EP (2) EP4599894A3 (https=)
JP (2) JP7568651B2 (https=)
KR (1) KR20220012281A (https=)
CN (1) CN113795255A (https=)
AU (2) AU2020280272B2 (https=)
BR (1) BR112021022602A2 (https=)
CA (1) CA3138081A1 (https=)
CL (1) CL2021003032A1 (https=)
DK (1) DK3972604T3 (https=)
ES (1) ES3039974T3 (https=)
FI (1) FI3972604T3 (https=)
HR (1) HRP20251001T1 (https=)
IL (1) IL286983B2 (https=)
LT (1) LT3972604T (https=)
MX (2) MX2021013942A (https=)
PL (1) PL3972604T3 (https=)
PT (1) PT3972604T (https=)
RS (1) RS67141B1 (https=)
SI (1) SI3972604T1 (https=)
TW (2) TW202537625A (https=)
WO (1) WO2020234782A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
JP7564347B2 (ja) 2021-09-03 2024-10-08 ノバルティス アーゲー 多発性硬化症を治療するためのｌｏｕ０６４
US20250032488A1 (en) 2021-12-14 2025-01-30 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
KR102834740B1 (ko) * 2023-04-10 2025-07-17 아주대학교산학협력단 Hsp10 또는 이의 항체를 유효성분으로 포함하는 만성 자발적 두드러기의 진단을 위한 바이오마커 조성물
WO2024235163A1 (zh) * 2023-05-12 2024-11-21 武汉人福创新药物研发中心有限公司 Btk抑制剂的用途和单剂量药物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2705719C (en) 2007-09-14 2016-10-11 Janssen Pharmaceutica N.V. Thieno-and furo-pyrimidine modulators of the histamine h4 receptor
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3092250A4 (en) 2014-01-08 2017-05-24 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016079669A1 (en) * 2014-11-19 2016-05-26 Novartis Ag Labeled amino pyrimidine derivatives
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije

Also Published As

Publication number Publication date
TWI868139B (zh) 2025-01-01
SI3972604T1 (sl) 2025-09-30
US20220184074A1 (en) 2022-06-16
RS67141B1 (sr) 2025-09-30
KR20220012281A (ko) 2022-02-03
MX2021013942A (es) 2022-01-04
EP3972604B1 (en) 2025-06-04
CN113795255A (zh) 2021-12-14
EP4599894A2 (en) 2025-08-13
PT3972604T (pt) 2025-08-26
TW202110450A (zh) 2021-03-16
AU2025252618A1 (en) 2025-11-06
AU2020280272A1 (en) 2021-11-18
EP3972604A1 (en) 2022-03-30
JP2024178168A (ja) 2024-12-24
AU2020280272B2 (en) 2025-07-24
EP4599894A3 (en) 2025-11-12
BR112021022602A2 (pt) 2022-01-04
CA3138081A1 (en) 2020-11-26
MX2024014626A (es) 2025-01-09
CL2021003032A1 (es) 2022-09-09
IL286983B2 (en) 2026-01-01
JP2022533981A (ja) 2022-07-27
LT3972604T (lt) 2025-09-10
WO2020234782A1 (en) 2020-11-26
JP7568651B2 (ja) 2024-10-16
IL286983B1 (en) 2025-09-01
HRP20251001T1 (hr) 2025-10-24
IL286983A (en) 2021-12-01
ES3039974T3 (en) 2025-10-28
FI3972604T3 (fi) 2025-09-01
PL3972604T3 (pl) 2025-09-22
US12419889B2 (en) 2025-09-23
US20250375446A1 (en) 2025-12-11
TW202537625A (zh) 2025-10-01

Similar Documents

Publication Publication Date Title
DK3972604T3 (da) Brutons tyrosinkinasehæmmer til anvendelse ved behandling af kronisk spontan urticaria
IL279258B (en) tyrosine kinase inhibitors
EP3813819A4 (en) CYCLIN-DEPENDENT KINASE INHIBITORS
EP3740207A4 (en) CYCLINE-DEPENDENT KINASE 7 (CDK7) INHIBITORS
EP3962908A4 (en) HETEROCYCLIC INHIBITORS OF TYROSINE KINASE
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3405192C0 (en) BRUTON'S TYROSINE KINASE INHIBITORS
MA42242A (fr) Inhibiteurs de la tyrosine kinase
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
DK3691620T3 (da) P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd
IL286727A (en) fgfr tyrosine kinase inhibitors for the treatment of urinary tract carcinoma
EP3804707A4 (en) KINASE INHIBITOR
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
LT3972603T (lt) Sjogreno sindromo gydymo būdai naudojant brutono tirozino kinazės inhibitorių
DK3643713T3 (da) Heterocykliske kinaseinhibitorer og deres anvendelse
EP3927700A4 (en) KINAS INHIBITORS
DK3658547T3 (da) Fremgangsmåde til fremstilling af n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
EP3448852A4 (en) NOVEL HETEROCYCLIC COMPOUNDS AS INHIBITORS OF TYROSINE KINASE BCR-ABL
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
EP3543239C0 (en) SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE
DK3679034T3 (da) 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-methylpropan-2-ol-derivater og dertilhørende forbindelser som il-7- og ifn-gamma-inhibitorer til behandling af autoimmunsygdomme og kronisk inflammation
EP3511327A4 (en) TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF
EP3902801A4 (en) Cyclin-dependent kinase inhibitors
IL290798A (en) Prodrugs of the tyrosine kinase inhibitor for treating cancer
IL277474B2 (en) Methods for treating chronic spontaneous urticaria using liglizumab